This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its ...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism spectrum disorder, with topline ...
Neuroimmunology has rapidly evolved as a critical field for understanding how inflammatory and immune processes shape the pathophysiology of brain ...
Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Prec ...
3don MSN
Genes linked to neuronal communication appear altered in immune cells of patients with depression
Neurons and white blood cells differ greatly in shape, function, and location within the body. However, researchers at the ...
Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form ...
VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...
In 2021, neurological diseases affected 3.40 billion individuals worldwide, corresponding to 43.1 % of the global population.
Dion’s recovery is a “full-time job” that could accelerate awareness for others.
METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results